|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM104A |
Gene summary for FAM104A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM104A | Gene ID | 84923 |
| Gene name | family with sequence similarity 104 member A | |
| Gene Alias | FAM104A | |
| Cytomap | 17q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q969W3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84923 | FAM104A | LZE2T | Human | Esophagus | ESCC | 8.71e-03 | 3.93e-01 | 0.082 |
| 84923 | FAM104A | LZE4T | Human | Esophagus | ESCC | 3.31e-14 | 3.93e-01 | 0.0811 |
| 84923 | FAM104A | LZE5T | Human | Esophagus | ESCC | 9.94e-03 | 2.35e-01 | 0.0514 |
| 84923 | FAM104A | LZE7T | Human | Esophagus | ESCC | 2.79e-05 | 4.48e-01 | 0.0667 |
| 84923 | FAM104A | LZE8T | Human | Esophagus | ESCC | 1.50e-13 | 2.54e-01 | 0.067 |
| 84923 | FAM104A | LZE20T | Human | Esophagus | ESCC | 2.95e-03 | 1.03e-01 | 0.0662 |
| 84923 | FAM104A | LZE22T | Human | Esophagus | ESCC | 5.08e-03 | 3.68e-01 | 0.068 |
| 84923 | FAM104A | LZE24T | Human | Esophagus | ESCC | 5.51e-23 | 6.60e-01 | 0.0596 |
| 84923 | FAM104A | LZE21T | Human | Esophagus | ESCC | 7.94e-06 | 4.56e-01 | 0.0655 |
| 84923 | FAM104A | LZE6T | Human | Esophagus | ESCC | 3.80e-09 | 4.82e-01 | 0.0845 |
| 84923 | FAM104A | P1T-E | Human | Esophagus | ESCC | 1.52e-03 | 2.75e-01 | 0.0875 |
| 84923 | FAM104A | P2T-E | Human | Esophagus | ESCC | 4.61e-26 | 4.53e-01 | 0.1177 |
| 84923 | FAM104A | P4T-E | Human | Esophagus | ESCC | 3.30e-28 | 5.90e-01 | 0.1323 |
| 84923 | FAM104A | P5T-E | Human | Esophagus | ESCC | 1.92e-18 | 3.14e-01 | 0.1327 |
| 84923 | FAM104A | P8T-E | Human | Esophagus | ESCC | 3.37e-29 | 5.88e-01 | 0.0889 |
| 84923 | FAM104A | P9T-E | Human | Esophagus | ESCC | 2.19e-17 | 4.54e-01 | 0.1131 |
| 84923 | FAM104A | P10T-E | Human | Esophagus | ESCC | 9.02e-37 | 6.25e-01 | 0.116 |
| 84923 | FAM104A | P11T-E | Human | Esophagus | ESCC | 2.21e-19 | 7.64e-01 | 0.1426 |
| 84923 | FAM104A | P12T-E | Human | Esophagus | ESCC | 1.36e-27 | 5.31e-01 | 0.1122 |
| 84923 | FAM104A | P15T-E | Human | Esophagus | ESCC | 1.16e-32 | 7.65e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM104A | SNV | Missense_Mutation | c.349N>C | p.Glu117Gln | p.E117Q | Q969W3 | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.628) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| FAM104A | insertion | Frame_Shift_Ins | rs769947396 | c.268dupC | p.Gln90ProfsTer6 | p.Q90Pfs*6 | Q969W3 | protein_coding | TCGA-AN-A0FY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| FAM104A | SNV | Missense_Mutation | novel | c.378N>G | p.Phe126Leu | p.F126L | Q969W3 | protein_coding | tolerated_low_confidence(0.65) | benign(0) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| FAM104A | SNV | Missense_Mutation | rs569512877 | c.155N>G | p.Ser52Cys | p.S52C | Q969W3 | protein_coding | tolerated_low_confidence(0.14) | benign(0.005) | TCGA-EK-A2RM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM104A | SNV | Missense_Mutation | novel | c.244N>A | p.Glu82Lys | p.E82K | Q969W3 | protein_coding | tolerated(0.16) | possibly_damaging(0.703) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FAM104A | SNV | Missense_Mutation | rs777461616 | c.272N>T | p.Thr91Ile | p.T91I | Q969W3 | protein_coding | deleterious(0) | benign(0.382) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| FAM104A | SNV | Missense_Mutation | novel | c.344G>T | p.Ser115Ile | p.S115I | Q969W3 | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| FAM104A | SNV | Missense_Mutation | rs768156778 | c.523G>A | p.Glu175Lys | p.E175K | Q969W3 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| FAM104A | SNV | Missense_Mutation | c.374N>A | p.Ala125Glu | p.A125E | Q969W3 | protein_coding | deleterious_low_confidence(0.03) | benign(0.4) | TCGA-B5-A0K9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM104A | SNV | Missense_Mutation | rs749964305 | c.383C>T | p.Ala128Val | p.A128V | Q969W3 | protein_coding | tolerated_low_confidence(0.17) | benign(0.003) | TCGA-RC-A7SB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |